Skip to main content

Table 1 Tachyzoite growth inhibition in infected villous explants after treatments

From: Brazilian strains of Toxoplasma gondii are controlled by azithromycin and modulate cytokine production in human placental explants

Strain/Drug

Parasite replication indexa

Inhibition of growth parasites (%)b

RH/without treatment

927.9 ± 344.7

–

 RH/AZ

241.1 ± 90.69*

74

 RH/ESP

181.4 ± 168.7*

80

 RH/PS

40,33 ± 25.58*

96

ME49/without treatment

705.4 ± 285.4

–

 ME49/AZ

166.0 ± 164.7*

76

 ME49/ESP

136,2 ± 110.7*

81

 ME49/PS

35.75 ± 16.50*

95

UD1/without treatment

2095.0 ± 608.9

–

 UD1/AZ

197.0 ± 232.1*

91

 UD1/ESP

135.9 ± 135.6*

94

 UD1/PS

21.45 ± 13.18*

99

UD2/without treatment

404.7 ± 226.4

–

 UD2/AZ

42.50 ± 24.92*

89

 UD2/ESP

26.53 ± 10.89*

93

 UD2/PS

29.14 ± 16.13*

93

  1. Tachyzoite growth inhibition in villous explants infected with RH, ME49, TgChBrUD1(UD1) or TgChBrUD2 (UD2) strains and treated with azithromycin (AZ), spiramycin (ESP) or pyrimethamine and sulfadiazine (150 μg/mL) (PS). aIndex of parasites replication was expressed in mean ± SD from three independent experiments in three replicates. bInhibition of growth parasites percentage in relation to untreated villous explants. *Statistically significant differences in relation to the absence of treatment (control) P < 0.05